Digital PCR DNA Fragment Sizing for Tumor-Derived HPV Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying and detecting DNA fragments of a particular size range, particularly in the context of viral nucleic acids associated with cancer, face challenges due to low sensitivity and specificity, as they cannot distinguish between tumor-derived and non-tumor-derived DNA, leading to false positives and inability to detect early-stage cancers.
Innovation Solution
A method involving digital PCR that fractionates DNA fragments into droplets, amplifies non-overlapping regions with primer/probe sets, and detects amplicon signals to quantify DNA fragments by size, distinguishing tumor-derived from non-tumor-derived viral DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR-based methods are used to detect viral DNA in circulation, then sensitivity for detecting viral sequences is improved, but specificity is worsened because the methods cannot distinguish between tumor-derived and non-tumor-derived viral DNA
Solution Approach 1:
The invention divides the detection process into two independent stages: first detecting the presence of viral DNA sequences, then separately determining fragment size distribution. This segmentation allows each stage to be optimized independently - the presence detection achieves high sensitivity while the size analysis provides the specificity needed to distinguish tumor-derived from non-tumor-derived DNA
Solution Approach 2:
The invention introduces fragment size as an intermediary parameter that mediates between the detected viral DNA and the conclusion of cancer presence. By measuring the size distribution of viral DNA fragments and comparing it to expected tumor-derived fragment patterns, the method achieves specific cancer detection while maintaining high sensitivity for viral DNA detection
2Quantity of substance
If current detection methods are used, then viral nucleic acids can be detected in circulation, but the ability to specifically identify cancer-associated viral DNA is lost due to confounding factors
Solution Approach 1:
The invention changes the measurement parameter from simply detecting viral DNA presence to measuring fragment size distribution. This parameter change transforms the detection capability - while maintaining the ability to detect viral nucleic acids, it adds the precision needed to identify cancer-associated DNA by comparing fragment size patterns against expected tumor-derived profiles
3Manufacturing precision
If gel electrophoresis and size-selective hybridization are used, then DNA fragment size can be determined, but sensitivity for detecting low-abundance tumor-derived DNA is reduced
Solution Approach 1:
The invention replaces mechanical separation methods (gel electrophoresis) with a molecular biology-based approach using nucleic acid amplification and fragment analysis. This substitution maintains the ability to determine fragment size while dramatically improving sensitivity by amplifying the target DNA sequences before size analysis, enabling detection of low-abundance tumor-derived DNA that would be undetectable by mechanical separation alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high sensitivity and specificity in detecting HPV-associated cancers, with 95% sensitivity and 100% specificity, enabling early detection of clinically undetected cancers and guiding treatment decisions.
Implementation Method 1
The Polymerase Chain Reaction (PCR) is unable to measure DNA fragments of a particular size range
Implementation Method 2
Current strategies for quantifying DNA fragments of a particular size generally involve the separation of DNA fragments by gel electrophoresis
Data Source
AI summary
Disclosed herein are DNA amplification methods for quantifying DNA fragments of a target DNA in a sample by size. This can be used, for example, to detect tumor-derived viral DNA in blood sample and distinguish it from larger viral DNA from non-tumor sources. In particular, disclosed herein are methods of detecting, monitoring or treating a human papilloma virus (HPV)-associated malignancy in a subject that involves detecting a presence or absence of at least one circulating tumor-derived HPV DNA in a sample from the subject. Kits for accomplishing the same are also provided.